Sujun Liu

Sujun Liu

Auto-generated profile, based on publicly available information

Sujun Liu

Hangzhou Third People's Hospital Zhejiang China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2023 in The Journal of Dermatology
Verified
Journal Article
Open access
LMLin Ma
Lin Ma
LZLitao Zhang
Litao Zhang
MKMichiko Kobayashi
Michiko Kobayashi
XTXiaohua Tao
Xiaohua Tao
QQQiufang Qian
Qiufang Qian
JZJianzhong Zhang
Jianzhong Zhang
Atopic dermatitis is a chronic inflammatory skin disease with a significant impact on the overall wellbeing of patients and their families. Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor approved for the treatment of mild‐to‐moderate atopic dermatitis in multiple countries. However, in the key pivotal trials, a low proportion of the overall patient population was Asian, therefore the safety and efficacy of crisaborole in the Asian population with atopic dermatitis remains unclear. CrisADe CLEAR was a multicenter, randomized, double‐blind, vehicle‐controlled, phase 3 study (NCT04360187) to assess the efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥2 years with mild‐to‐moderate atopic dermatitis involving ≥5% treatable body surface area. Patients were randomly assigned 2:1 to receive crisaborole or vehicle twice daily for 28 days. The primary endpoint was percentage change from baseline in the Eczema Area and Severity Index total score at day 29. Additional endpoints were improvement and success per Investigator's Static Global Assessment score at day 29 and change from baseline on the Peak Pruritus Numerical Rating Scale at week 4. Safety was assessed using rates of treatment emergent adverse events, serious adverse events, and clinically significant changes in vital signs and clinical laboratory parameters. Crisaborole‐treated patients showed a significantly greater reduction versus vehicle in percentage change from baseline in Eczema Area and Severity Index total score at day 29 (P = 0.0002). Response rates for achievement of Investigator's Static Global Assessment improvement and success at day 29 were significantly higher for patients treated with crisaborole versus vehicle (P = 0.0124 and P = 0.0078, respectively). Crisaborole‐treated patients showed a significantly greater reduction versus vehicle in change from baseline on the Peak Pruritus Numerical Rating Scale at week 4 (P = 0.0009). No new safety signals were identified. Treatment with crisaborole was effective and well tolerated in Chinese and Japanese patients with mild‐to‐moderate atopic dermatitis.

21 March 2013 in Surgery Today
Verified
Journal Article
Closed access
PDF file
YSYing-Mo Shen
Ying-Mo Shen
JCJie Chen
Jie Chen
MTMao-Lin Tian
Mao-Lin Tian
SYShuo Yang
Shuo Yang
SLSu-Jun Liu
Su-Jun Liu
MWMing-Gang Wang
Ming-Gang Wang

13 June 2011 in Natural Product Research
Verified
Journal Article
Closed access
SLSujun Liu
Sujun Liu
MCMei Cao
Mei Cao
DLDaxu Li
Daxu Li
JZJie Zhang
Jie Zhang
SFSu Feng
Su Feng
JZJian Zhao
Jian Zhao
Sinojackia sarcocarpa L.Q. Luo has high aesthetic value, which is clinically used to treat diseases such as the variations of arthritis, thromboangiitis obliterans, angina pectoris as well as many other diseases. Pentacyclic triterpenoids are the main pharmacological effective compounds. High-speed counter-current chromatography method was performed on a Midi-DE centrifuge at 25°C. The solvent system was n-hexane–ethylacetate–methanol–water (10 : 5 : 3 : 1, v/v). Peak fractions were collected according to the elution profile for subsequent high-performance liquid chromatography analysis. The structure identification was performed by ultraviolet, infrared, mass spectrometry, 1H-NMR and 13C-NMR. Compound 2α,3α,19β,23β-tetrahydroxyurs-12-en-28-oic acid and 2α,3α,23β-trihydroxyurs-12-en-28-oic acid were purified from the plant of Styracaceaen genius for the first time, whose purities were 96.57% and 97.33%, respectively. Compared with the same dose of oral 5-fluorouracil with 57.6% inhibition rate, the S180 tumour inhibition rates of 20 mg kg−1 d−1 two compounds were 59.5% and 48.9%, respectively.